TFF Pharmaceuticals, Inc., an Austin, Texas-based biopharmaceutical company focused on developing and commercializing new inhalation drug products for the treatment of chronic respiratory diseases and lung conditions, closed an $8.17m Series A funding.
The proceeds from this transaction will provide additional funding for the progress of the company’s current research and development programs.
Led by Glenn Mattes, CEO, TFF Pharmaceuticals initially focuses on dry powder drugs for inhalation of both biologic and small molecule drugs that currently cannot be formulated for dry powder delivery by other means.
The company’s technology, which is a combination of more than 30 patents and applications, is licensed exclusively from the University of Texas at Austin.
TFF also expanded its its leadership team with the appointment of Kirk Coleman as Chief Financial Officer and Randy Thurman to the Board of Directors and chairman of its audit committee.